Filmed in April 2021 – Backed by extensive clinical evidence, the Decipher Prostate Genomic Classifier helps clinicians and their patients with prostate cancer make informed decisions for personalized treatment.
Join Dr. Matthew Cooperberg, M.P.H., University of California, Dr. Robert Den, Thomas Jefferson University, and Dr. Sanoj Punnen, University of Miami, for their in-depth conversation about the use of biomarkers in active surveillance for low-risk and favorable intermediate-risk prostate cancer patients.
This video explores the evolving role of genomic biomarkers, like Decipher Prostate, in prostate cancer management post diagnosis, helping clinicians make more informed treatment decisions. For low-risk prostate cancer patients, combined with imaging and clinical data, genomic tests like Decipher Prostate may help determine whether to go on active surveillance or get immediate definitive therapy and further help tailor active surveillance.
Explore how biomarkers are helping determine active surveillance protocols for patients with prostate cancer and how Decipher Prostate by Veracyte offers specific insights into aggressive tumor biology.
Working together with the cancer community, our mission is to advance prostate cancer care with exceptional genomic testing for personalized treatment planning.
Key topics
- 0:00 – Introduction
- 2:30 – Integrating Biomarkers With Imaging
- 17:30 – Negative Predictive Value for MRI
- 20:30 – Active Surveillance Paradigms
- 24:30 – Low-Risk Disease Treatment Discussion
Speakers
Matthew Cooperberg, M.D., M.P.H., FACS
University of California San Francisco
Robert Den, M.D.
Thomas Jefferson University
Sanoj Punnen, M.D.
University of Miami
Tags
On Demand
Decipher Prostate